MultiValent Biotherapies is developing a peptide-like drug conjugate that hits two validated targets to treat prostate cancer. This clinical-stage asset was licensed from China-based Coherent Biopharma.
The post New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug appeared first on MedCity News.
